Get started
Work

Abstract PS5-02-28: Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps5-02-28
Authors: K. Kalinsky, P. Schmid, E. de Azambuja, S. Loi, S. Kim, C. Yam, B. Rapoport, S. Im, B. Pistilli, W. Mchayleh, D. W. Cescon, J. Watanabe, M. Bañuelas, R. Freitas-Junior, A. Lortholary, D. Gary, K. Caldwell, E. Harting, S. M. Tolaney
Institutions: Emory University, Winship Cancer Institute, Queen Mary University of London, Barts Cancer Institute, Université Libre de Bruxelles, Institut Jules Bordet, Peter MacCallum Cancer Centre, Asan Medical Center, University of Ulsan, The University of Texas MD Anderson Cancer Center, The Medical Oncology Centre of Rosebank, Seoul National University, Seoul National University Hospital, Institut Gustave Roussy, AdventHealth Orlando, AdventHealth, University Health Network, Princess Margaret Cancer Centre, Juntendo University, Universidade Federal de Goiás, Hôpital privé du Confluent, Gilead Sciences (United States), Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W7130688996
Cites:
Cited by:
Related to: